Skip to main content
EVO logo

Evotec SE (EVO) Stock: Price, Forecast & Analyst Target

Evotec SE (EVO) — MoonshotScore 21/100 (Weak band), calculated Nov 18, 2026. Price $1.45 (-0.68%), as of the Nov 19, 2026 trading session; market cap $515M.

Educational signal · not a buy or sell recommendation · How to read this

$1.45 −$0.01 (-0.68%) Market Cap $515M

Evotec SE · EVO · NASDAQ

Evotec SE is a drug discovery and development partner for the pharmaceutical and biotechnology industry. The company develops pharmaceutical products across various therapeutic areas and has collaboration agreements with multiple companies.

Price as of Nov 19, 2026

Key Statistics

21 of 100

MoonshotScore v2 · Evotec SE (EVO)

Weak
Business Quality Average (44)
Financial Safety Strained (21)
Valuation Fair (75)
Growth Durability Fading (27)
Momentum Slipping (35)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fragile balance sheet and weak growth, though quality is only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Average; Financial Safety: Strained; Valuation: Fair; Growth Durability: Fading; Momentum: Slipping.

  • quarterly revenue €165M (Q3 FY2026, quarter ended Sep 2026)
  • EPS beat 2 of the last 8 reports
  • Altman Z -0.14 · Piotroski F 5

Holding back: balance-sheet strain, soft growth

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for EVO (52 recorded, newest six shown)
RecordedScoreBand
21Weak
21Weak
22Weak
22Weak
21Weak
21Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.45
Change on the day-0.68%
52-week range$1.33 – $3.87
Market capitalisation$515M—
Shares traded on the day116.3K

Price & events

Other perspectives

Council score for Evotec SE (EVO): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Weak
Valuation Moderate
Growth Durability Weak
Momentum Weak

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 13, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Weak
ROE Negative
Gross Margin Weak

Read on: Nov 13, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 13, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Evotec SE (EVO), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Evotec SE (EVO) is listed on NASDAQ. It employs 4,553 people and is led by Christian Wojczewski. In Q3 FY2026 it reported revenue of €165M and net income of -€27M. The market values it at $515M.

2 · Latest results

What do the latest results show for Evotec SE (EVO)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of €165M. Against analyst estimates the company has EPS beat 2 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026€165M-€27M-€0.08 (diluted)
Q2 FY2026€146M-€47M-€0.13 (diluted)
Q1 FY2026€159M-€124M-€0.35 (diluted)
Q4 FY2025€251M€14M€0.04 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Evotec SE (EVO)?

Short answer · as of

The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is balance-sheet strain, soft growth. The distress and quality screens read Altman Z -0.14 · Piotroski F 5. Trailing ratios: ROE -25.6% · ROA -12.0% · current ratio 2.32 · earnings yield -34.6% · free-cash-flow yield -24.2%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -0.14 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-25.6%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
4 · What to check next?

What should you watch next at Evotec SE (EVO)?

Short answer · as of

Current published price targets run low $2.00 · high $4.00 · consensus $3.00 · median $3.00 against a quoted price of $1.45 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Evotec SE compare with its peers?

Short answer

Evotec SE's score ranks tied for 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Cronos Group Inc. (CRON) Same industry, near in market value$3.17 Nov 18, 2026$1.16B95 5-pillar Nov 18, 2026
Kamada Ltd. (KMDA) Same industry, near in market value$8.07 Nov 18, 2026$466M87 5-pillar Nov 18, 2026
Embecta Corp. (EMBC) Same industry, near in market value$6.19 Nov 19, 2026$351M71 5-pillar Nov 18, 2026
Collegium Pharmaceutical, Inc. (COLL) Same industry, near in market value$25.93 Nov 18, 2026$806M58 5-pillar Nov 18, 2026
Ironwood Pharmaceuticals, Inc. (IRWD) Same industry, near in market value$4.78 Nov 18, 2026$791M39 5-pillar Nov 18, 2026
Alpha Teknova, Inc. (TKNO) Same industry, near in market value$7.81 Nov 19, 2026$491M34 5-pillar Nov 18, 2026
Harrow Health, Inc. (HROW) Same industry, near in market value$32.16 Nov 18, 2026$1.21B33 5-pillar Nov 18, 2026
SNDL Inc. (SNDL) Same industry, near in market value$1.24 Nov 19, 2026$302M32 5-pillar Nov 18, 2026
Spyre Therapeutics, Inc. (SYRE) Named competitor$97.63 Nov 19, 2026$9.27B26 5-pillar Nov 18, 2026
Emergent BioSolutions Inc. (EBS) Same industry, near in market value$5.15 Nov 19, 2026$265M24 5-pillar Nov 18, 2026
Evotec SE (EVO) — this page$1.45$515M21
Evolus, Inc. (EOLS) Same industry, near in market value$7.00 Nov 19, 2026$463M21 5-pillar Nov 18, 2026
Lifecore Biomedical, Inc. (LFCR) Same industry, near in market value$6.37 Nov 19, 2026$241M21 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$2.00 – $4.00
Consensus target
$3.00
Median target
$3.00

Consensus record · Captured .

Measured against a quoted price of $1.45 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
12
Identified insiders
6
Purchases
3
Sales
3
Other transactions
6

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held EVO in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported EVO in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Evotec SE (EVO)?

Read these with our analysis →

Investor Questions: EVO Stock

These answers are editorial: 1 of these 9 answers is drawn from the EVO research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for EVO?

EVO carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Evotec SE is a drug discovery and development partner for the pharmaceutical and biotechnology industry.

Is EVO a good stock to buy?

Stock Expert AI does not rate EVO buy, sell or hold. Evotec SE carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the EVO stock price today?

The last price recorded for Evotec SE (EVO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the EVO price target?

The analyst consensus price target for Evotec SE (EVO), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for EVO?

Evotec SE faces several key risks, including clinical trial failures, regulatory hurdles, competition, and economic downturns. Clinical trial failures can significantly impact the company's revenue and profitability, as milestone payments and royalties may be delayed or canceled. Regulatory changes and stricter approval requirements can also increase the time and cost of developing new drugs.

What are the key factors to evaluate for EVO?

Evotec SE (EVO) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. The application of AI and ML in drug discovery is expected to significantly reduce the time and cost of developing new drugs. Not financial advice.

How frequently does EVO data refresh on this page?

EVO's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven EVO's recent stock price performance?

Evotec SE (EVO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong collaboration network with major pharmaceutical companies. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider EVO overvalued or undervalued right now?

Evotec SE (EVO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 20 figures on this page — 12 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.